Comparison of end-tidal carbon monoxide measurements with direct antiglobulin tests in the management of neonatal hyperbilirubinemia

J Perinatol. 2020 Oct;40(10):1513-1517. doi: 10.1038/s41372-020-0652-y. Epub 2020 Mar 19.

Abstract

Objective: Determine whether management of neonatal hyperbilirubinemia differs if one used end-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc) measurements instead of direct antiglobulin test (DAT) results to assess the severity of hemolysis.

Study design: Retrospective chart review of infants with total bilirubin and ETCOc levels measured from July 2016 to August 2018. The reported treatment is the hypothetical management infants might have received had there been strict adherence to American Academy of Pediatrics guidelines, rather than the actual management they received.

Result: Only 27.2% of 191 DAT(+) infants were hemolyzing based on ETCOc, while 29.1% of DAT (-) infants were hemolyzing based on ETCOc. Management of 18 (9.4%) infants differed depending if ETCOc or DAT were used to determine hemolysis. Eight fewer infants would have received phototherapy if ETCOc was used.

Conclusions: ETCOc is a more accurate determinant of hemolysis in the newborn, and its use can lead to less phototherapy.

MeSH terms

  • Bilirubin
  • Carbon Monoxide*
  • Child
  • Coombs Test
  • Humans
  • Hyperbilirubinemia / diagnosis
  • Hyperbilirubinemia / therapy
  • Hyperbilirubinemia, Neonatal* / diagnosis
  • Hyperbilirubinemia, Neonatal* / therapy
  • Infant, Newborn
  • Retrospective Studies

Substances

  • Carbon Monoxide
  • Bilirubin